June 21, 2013

Differential Effect of Everolimus on Progression of Early and Late Cardiac Allograft Vasculopathy in Current Clinical Practice.


Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177

Warning: Invalid argument supplied for foreach() in /nfs/c04/h03/mnt/65750/domains/transplantnow.com/html/wp-content/themes/nephrology/scripts/pubmed.php on line 177
.   .   

CAV remains the leading cause of long-term death in heart transplant recipients. This retrospective analysis of prospectively collected data (IVUS) demonstrated everolimus independently reduced the odds for early CAV (0.14 [0.01_0.77]; p 0.02) but it did not appear to influence late CAV progression. High dose statin use was favorably associated with a reduction in both early and late CAV.

Cardiac Transplantation

Tags: , , , , , , , ,